4.8 Article

RalA suppresses early stages of Ras-induced squamous cell carcinoma progression

Journal

ONCOGENE
Volume 29, Issue 1, Pages 45-55

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2009.307

Keywords

Ral; Ras; squamous cell carcinoma; E-cadherin; tumor progression

Funding

  1. NIGMS
  2. NIDCR

Ask authors/readers for more resources

Ras proteins activate Raf and PI-3 kinases, as well as exchange factors for RalA and RalB GTPases. Many previous studies have reported that the Ral-signaling cascade contributes positively to Ras-mediated oncogenesis. Here, using a bioengineered tissue model of early steps in Ras-induced human squamous cell carcinoma of the skin, we found the opposite. Conversion of Ras-expressing keratinocytes from a premalignant to malignant state induced by decreasing E-cadherin function was associated with and required an approximately two to threefold decrease in RalA expression. Moreover, direct knockdown of RalA to a similar degree by shRNA expression in these cells reduced E-cadherin levels and also induced progression to a malignant phenotype. Knockdown of the Ral effector, Exo84, mimicked the effects of decreasing RalA levels in these engineered tissues. These phenomena can be explained by our finding that the stability of E-cadherin in Ras-expressing keratinocytes depends upon this RalA signaling cascade. These results imply that an important component of the early stages in squamous carcinoma progression may be a modest decrease in RalA gene expression that magnifies the effects of decreased E-cadherin expression by promoting its degradation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer

Fen Ma, Seiji Arai, Keshan Wang, Carla Calagua, Amanda R. Yuan, Larysa Poluben, Zhongkai Gu, Joshua W. Russo, David J. Einstein, Huihui Ye, Meng Xiao He, Yu Liu, Eliezer Van Allen, Adam G. Sowalsky, Manoj K. Bhasin, Xin Yuan, Steven P. Balk

Summary: This study reveals the importance of Wnt/beta-catenin signaling in prostate cancer, showing its role in stem cell maintenance and invasion. It identifies new effectors and drivers of this pathway in prostate cancer, such as ROR1 and APC genomic loss. The findings suggest that targeting Wnt/beta-catenin signaling may be a potential therapeutic strategy for prostate cancer.

CANCER RESEARCH (2022)

Article Oncology

Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications

Xin Dong, Hui Xue, Fan Mo, Yen-Yi Lin, Dong Lin, Nelson K. Y. Wong, Yingqiang Sun, Scott Wilkinson, Anson T. Ku, Jun Hao, Xinpei Ci, Rebecca Wu, Anne Haegert, Rebecca Silver, Mary-Ellen Taplin, Steven P. Balk, Joshi J. Alumkal, Adam G. Sowalsky, Martin Gleave, Colin Collins, Yuzhuo Wang

Summary: This study aimed to develop clinically relevant models for studying ADT-induced prostate cancer dormancy. The researchers established 11 ADT-induced dormant prostate cancer models that closely mimicked the clinical courses of ADT-treated prostate cancer and identified two ADT-induced dormancy subtypes that differed in morphology, gene expression, and relapse rates. They also discovered transcriptomic differences in precastration PDXs that predisposed the dormancy response to ADT and developed a dormancy subtype-based, predisposed gene signature that was significantly associated with ADT response in hormonal naive prostate cancer and clinical outcome in castration-resistant prostate cancer treated with ADT or androgen-receptor pathway inhibitors.

MOLECULAR CANCER RESEARCH (2022)

Article Urology & Nephrology

Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer

John R. Bright, Rosina T. Lis, Anson T. Ku, Nicholas T. Terrigino, Nichelle C. Whitlock, Shana Y. Trostel, Nicole Carrabba, Stephanie A. Harmon, Baris Turkbey, Scott Wilkinson, Adam G. Sowalsky

Summary: The study evaluated the ability of antibodies against PSMA to specifically detect residual tumor in patients treated with iADT and enzalutamide. The results showed that PSMA reacted positively with tumor in all cases and had high sensitivity but low specificity for benign regions. PSMA could also identify highly dedifferentiated prostate carcinomas, indicating its potential as a valuable marker.

JOURNAL OF UROLOGY (2022)

Article Oncology

Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer

Adam G. Sowalsky, Ines Figueiredo, Rosina T. Lis, Ilsa Coleman, Bora Gurel, Denisa Bogdan, Wei Yuan, Joshua W. Russo, John R. Bright, Nichelle C. Whitlock, Shana Y. Trostel, Anson T. Ku, Radhika A. Patel, Lawrence D. True, Jonathan Welti, Juan M. Jimenez-Vacas, Daniel Nava Rodrigues, Ruth Riisnaes, Antje Neeb, Cynthia T. Sprenger, Amanda Swain, Scott Wilkinson, Fatima Karzai, William L. Dahut, Steven P. Balk, Eva Corey, Peter S. Nelson, Michael C. Haffner, Stephen R. Plymate, Johann S. de Bono, Adam Sharp

Summary: This study demonstrates that further analytical validation and clinical qualification are required before AR-V7 can be considered for clinical use in CSPC as a predictive biomarker.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood

Jennifer Wilkinson Carlisle, Caroline S. Jansen, Maria Andrea Cardenas, Ewelina Sobierajska, Adriana Moon Reyes, Rachel Greenwald, Luke Del Balzo, Nataliya Prokhnevska, Omer Kucuk, Bradley C. Carthon, Patrick Connor Mullane, Adeboye Osunkoya, Deborah Baumgarten, Fares Hosseinzadeh, Scott Wilkinson, Ross Lake, Adam G. Sowalsky, Yuan Liu, Viraj A. Master, Mehmet A. Bilen, Haydn Kissick

Summary: This study identifies potential immunological biomarkers that can predict therapeutic response in patients with advanced renal cell carcinoma (RCC). Assessing changes in T cells in the peripheral blood and tumor microenvironment, the researchers found that patients with the highest increase in specific activated T cells had the best antitumor immune response and clinical benefit.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Editorial Material Oncology

Unpacking circulating tumor DNA lends insight into prostate cancer biology and the clonal dynamics of metastasis

David Y. Takeda, Adam G. Sowalsky

Summary: A recent report in Nature demonstrates that whole-genome sequencing of circulating tumor DNA from patients with metastatic PCa can inform on the subclonal composition of metastatic disease and infer patterns of gene expression.

CANCER CELL (2022)

Article Biology

Defining cellular population dynamics at single-cell resolution during prostate cancer progression

Alexandre A. Germanos, Sonali Arora, Ye Zheng, Erica T. Goddard, Ilsa M. Coleman, Anson T. Ku, Scott Wilkinson, Hanbing Song, Nicholas J. Brady, Robert A. Amezquita, Michael Zager, Annalysa Long, Yu Chi Yang, Jason H. Bielas, Raphael Gottardo, David S. Rickman, Franklin W. Huang, Cyrus M. Ghajar, Peter S. Nelson, Adam G. Sowalsky, Manu Setty, Andrew C. Hsieh

Summary: In this study, we found that the expansion of castration-resistant intermediate luminal cells is associated with treatment resistance and poor prognosis in prostate cancer. The transformed epithelial cells and associated fibroblasts create a microenvironment that promotes pro-tumorigenic immune infiltration, which is influenced by androgen levels. Androgen-independent prostate cancer leads to significant diversification of intermediate luminal cell populations with varying androgen signaling activities, which are inversely correlated with proliferation and mRNA translation. The findings suggest that targeting translation inhibition could potentially lead to epithelial cell death, loss of pro-tumorigenic signaling, and decreased tumor heterogeneity.

ELIFE (2022)

Editorial Material Oncology

Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy

Scott Wilkinson, Adam G. Sowalsky

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Meeting Abstract Oncology

STEM-LIKE CD8 T-CELLS RESIDING IN ANTIGEN PRESENTING IMMUNE NICHES ARE PROGNOSTIC FOR LOCAL CONTROL IN BRAIN METASTASES AND ARE SUSTAINED FOLLOWING RADIATION THERAPY

Caroline Jansen, Prasanthi Chappa, Nataliya Prokhnevska, Maria Cardenas, Roshan Prabhu, Jim Zhong, Kimberly Hoang, Subir Goyal, Suzanna Logan, Jeffrey Olson, Edjah Nduom, Luke del Balzo, Kirtesh Patel, Stuart Burri, Anthony Asher, Scott Wilkinson, Ross Lake, Kristin Higgins, Pretesh Patel, Vishal Dhere, Mylin Torres, Adam Sowalsky, Mohammad Khan, Haydn Kissick, Zachary Buchwald

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

Progression of prostate cancer reprograms MYC-mediated lipid metabolism via lysine methyltransferase 2A

Nichelle C. Whitlock, Margaret E. White, Brian J. Capaldo, Anson T. Ku, Supreet Agarwal, Lei Fang, Scott Wilkinson, Shana Y. Trostel, Zhen-Dan Shi, Falguni Basuli, Karen Wong, Elaine M. Jagoda, Kathleen Kelly, Peter L. Choyke, Adam G. Sowalsky

Summary: Our study reveals that the epigenetic activity of transcription factor oncogenes undergoes a shift during prostate cancer progression, leading to distinctive effects on metabolism. These epigenetically-driven changes in lipid metabolism may serve as novel targets for the development of imaging agents and therapeutics.

DISCOVER ONCOLOGY (2022)

Meeting Abstract Oncology

Bcl-2 inhibitor enhances anti-androgen therapy induced regression of castration sensitive prostate cancer.

Rahim Hirani, Subhiksha Nandakumar, Teja Kalidindi, Deborah Fidele, Harisha Rajanala, Ying Mazzu, Yuki Yoshikawa, Lina Jehane, Gwo-Shu Mary Lee, Elisa de Stanchina, Adam Sowalsky, Michael J. Morris, Heiko Schoder, Naga Vara Kishore Pillarsetty, Lorelei A. Mucci, Daniel Danila, Goutam Chakraborty, Philip W. Kantoff

CANCER RESEARCH (2021)

Meeting Abstract Oncology

An immunologic niche of antigen presenting cells and stem-like CD8+T-cells is present in non-small cell lung cancer brain metastases.

Caroline S. Jansen, Luke del Balzo, Roshan Prabhu, Suzanna Logan, Prasanthi Chappa, Kirtesh Patel, Scott Wilkinson, Ross Lake, Hui-Kuo G. Shu, Jim Zhong, Vishal Dhere, Jeffrey Olson, Adam G. Sowalsky, Mohammad K. Khan, Haydn T. Kissick, Zachary S. Buchwald

CLINICAL CANCER RESEARCH (2021)

Article Oncology

EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

Katherine L. Morel, Anjali Sheahan, Deborah L. Burkhart, Sylvan C. Baca, Nadia Boufaied, Yin Liu, Xintao Qiu, Israel Canadas, Kevin Roehle, Max Heckler, Carla Calagua, Huihui Ye, Constantia Pantelidou, Phillip Galbo, Sukanya Panja, Antonina Mitrofanova, Scott Wilkinson, Nichelle C. Whitlock, Shana Y. Trostel, Anis A. Hamid, Adam S. Kibel, David A. Barbie, Atish D. Choudhury, Mark M. Pomerantz, Christopher J. Sweeney, Henry W. Long, David J. Einstein, Geoffrey Shapiro, Stephanie K. Dougan, Adam G. Sowalsky, Housheng Hansen He, Matthew L. Freedman, Steven P. Balk, Massimo Loda, David P. Labbe, Brian M. Olson, Leigh Ellis

Summary: Combination of EZH2 inhibition and anti-PD-1 has been shown to enhance antitumor immune responses in prostate cancer by activating the dsRNA-STING-ISG stress response signaling; EZH2 inhibition upregulates genes involved in antigen presentation and interferon response, suggesting it as a therapeutic direction to enhance prostate cancer response to PD-1 CPI.

NATURE CANCER (2021)

No Data Available